Drug
Lazertinib clinical trials
Also written JNJ-73841937 and YH25448.
- studies test it
- 30
- open now
- 6
- in phase 3
- 3
- first study started
- 2017
Keep track of what changes. Save the lazertinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
30 studies that test it; most in 2023 (9)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 6 |
| 2022 | 4 |
| 2023 | 9 |
| 2024 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 18
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 13
Janssen Research & Development, LLC (12) · Yonsei University (4) · Yuhan Corporation (4) · Sehhoon Park (2) · Jin Hyoung Kang (2) · ETOP IBCSG Partners Foundation (1) · Latin American Cooperative Oncology Group (1) · Memorial Sloan Kettering Cancer Center (1)
Often tested with
Tested in the same studies.
Amivantamab (6) · Pemetrexed (5) · Carboplatin (4) · Midazolam (1) · Rosuvastatin (1) · Metformin (1) · Itraconazole (1) · Rifampin (1)
Studies
Open first, then newest update. How each study uses lazertinib is read from its arms, and is right about nine times in ten.
Testing it · 30
- A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2Janssen Research & Development, LLCNCT06667076Written as Lazertinib
- A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLCRecruitingPhase 2Janssen Research & Development, LLCNCT07586202Written as Lazertinib
- Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib TreatmentRecruitingPhase 2Sehhoon ParkNCT06106802Written as Lazertinib
- To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET DysregulationRecruitingPhase 2Abion IncNCT05541822Written as Lazertinib
- Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib MonotherapyNot yet recruitingPhase 2Yonsei UniversityNCT06020989Written as Lazertinib+Pemetrexed+Carboplatin
- A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation TherapyRecruitingPhase 2Sung Yong LeeNCT05338619Written as Lazertinib
- Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain MetastasesTerminatedPhase 2Jin Hyoung KangNCT05477615Written as Lazertinib
- Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior LazertinibCompletedPhase 2Yonsei UniversityNCT05786430Written as Lazertinib/Pemetrexed/Carboplatin
- A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingPhase 3Janssen Research & Development, LLCNCT04487080Written as Lazertinib
- A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib FailureActive, not recruitingPhase 3Janssen Research & Development, LLCNCT04988295Written as Lazertinib
- Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor MutationsCompletedPhase 2Latin American Cooperative Oncology GroupNCT05299125Written as Lazertinib
- Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve PatientsActive, not recruitingPhase 2Sehhoon ParkNCT05463224Written as Lazertinib group
- Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung CancerActive, not recruitingPhase 2Yonsei UniversityNCT06268210Written as Lazertinib+Pemetrexed+Carboplatin
- A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung CancerActive, not recruitingPhase 1Janssen Research & Development, LLCNCT04077463Written as Lazertinib
- Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)CompletedPhase 3Yuhan CorporationNCT04248829Written as Lazertinib 240 mg/160 mg
- Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKIActive, not recruitingPhase 2ETOP IBCSG Partners FoundationNCT05601973Written as Lazertinib
- A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT04965090Written as Lazertinib
- A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 1/2Janssen Research & Development, LLCNCT04075396Written as Lazertinib
- A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937)CompletedPhase 1Janssen Research & Development, LLCNCT05112952Written as Lazertinib
- Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLCCompletedPhase 1/2Yuhan CorporationNCT03046992Written as YH25448
See all 30 studies that test lazertinib →
Given in every arm · 6 — lazertinib is usual care beside what is tested
- A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerRecruitingPhase 2Janssen Research & Development, LLCNCT05498428Written as Lazertinib
- A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & SmokerRecruitingPhase 2National Cancer Center, KoreaNCT06156527Written as Lazertinib
- A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung CancerActive, not recruitingPhase 3Janssen Research & Development, LLCNCT05388669Written as Lazertinib
- Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung CancerActive, not recruitingPhase 1Janssen Research & Development, LLCNCT02609776Written as Lazertinib
- Premedication to Reduce Amivantamab Associated Infusion Related ReactionsActive, not recruitingPhase 2Janssen Research & Development, LLCNCT05663866Written as Lazertinib
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus LazertinibActive, not recruitingPhase 2Janssen Research & Development, LLCNCT06120140Written as Lazertinib
Codes
What other systems call lazertinib · ClinicalTrials.gg INT001347
- MeSH (NLM) C000707992lazertinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 4A2Y23XK11LAZERTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q105337288lazertinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C148147LazertinibOne source FDA
- DrugBank DB16216One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000707992 | lazertinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 4A2Y23XK11 | LAZERTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q105337288 | lazertinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C148147 | Lazertinib | One source FDA |
| DrugBank | DB16216 | — | One source Wikidata |
Also registered as lazertinib mesylate (UNII WUT449BEG5).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.